



Chemoprevention Options to Reduce Breast Cancer Risk

Drug Name	Tamoxifen			Aromatase
	20MG (standard dose)	5MG (low dose)	Raloxifene	Inhibitors
How it Works	Changes estrogen receptor		Changes estrogen receptor	Reduces circulating estrogen
When to Take	Before or after menopause		After menopause	After menopause
Benefits	 Cuts risk in half (example: 30% to 15%) Strengthens bones Decreases (improves) lipids a bit 		 Cuts risk by almost half (example: 30% to 19%) Strengthens bones to prevent bone loss (osteoporosis) and hip fracture 	Cuts risk by more than half (example: 30% to 13%)
Risks	 Endometrial cancer (<1/100) Venous blood clots (DVT/PE); 4/1,000 risk after menopause only 	May not have same risks as 20MG dose	Venous blood clots (DVT/PE); 1/1,000 risk	 Weakens bones Increases lipids a bit
Side Effects	 Hot flashes (varies from 1/3 none, 1/3 mild, 1/3 a lot) Vaginal dryness Cataracts, slightly increased 	 May have fewer side effects than 20MG dose Small increase in hot flashes 	Hot flashes (15% likely)	 Hot flashes (30% + likely) Vaginal dryness Joint pain
Cost	Lowest		Low	May be higher
Other Info	 Long research history Must stop taking before major surgery May interact with depression/anxiety medicines 	 Not as much research history Dose not FDA- approved Must stop taking before major surgery May interact with depression/anxiety medicines 	 Long research history FDA approved to treat osteoporosis 	Not as much research history

Each of these medicines are taken as a pill once daily for five years. Many side effects can be treated with other medicines. Or, you can always choose to stop taking the drug. Typically, we do not recommend taking one of these medicines until after age 35 and after you are done having children.

Huntsman Cancer Institute Family Cancer Assessment Clinic | 801-587-9555 | huntsmancancer.org/fcac

For more patient education information: Call 1-888-424-2100 toll free • Email cancerinfo@hci.utah.edu • Visit huntsmancancer.org/factsheets Produced by HCI © 2019 • Approved by a team of medical, health, and communications specialists • June 2019 • Review Date June 2022